<DOC>
	<DOCNO>NCT00454350</DOCNO>
	<brief_summary>This study measure serum level active Vitamin D compound circulate hemodialysis subject treat either doxercalciferol injection ( Hectorol® ) Zemplar® ( paricalcitol injection ) .</brief_summary>
	<brief_title>A Phase 4 Pharmacokinetic Study Hectorol Injection Zemplar Injection CKD Subjects Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Hyperparathyroidism</mesh_term>
	<mesh_term>Hyperparathyroidism , Secondary</mesh_term>
	<mesh_term>1 alpha-hydroxyergocalciferol</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<criteria>The subject must receive hemodialysis three time per week minimum three month . The subject must receive intravenous doxercalciferol paricalcitol dialysis session ( three time weekly ) minimum 12 week prior Screening . At Screening Visit subject 's laboratory measurement must within follow range : Serum iPTH measurement 150800 pg/mL ; Corrected calcium measurement ≤ 10.5 mg/dL ; Serum phosphorus measurement ≤ 7 mg/dL Any ongoing use counter prescription vitamin D preparation except doxercalciferol paricalcitol injection multivitamin . History heparininduced thrombocytopenia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Hectorol ( doxercalciferol injection )</keyword>
	<keyword>Zemplar ( paricalcitol injection )</keyword>
</DOC>